Identification

Name
Droxicam
Accession Number
DB09215
Type
Small Molecule
Groups
Withdrawn
Description

Droxicam is a non-steroidal anti-inflammatory drug of the oxicam class. A prodrug of Piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
F24ADO1E2D
CAS number
90101-16-9
Weight
Average: 357.34
Monoisotopic: 357.04194164
Chemical Formula
C16H11N3O5S
InChI Key
OEHFRZLKGRKFAS-UHFFFAOYSA-N
InChI
InChI=1S/C16H11N3O5S/c1-18-13-14(10-6-2-3-7-11(10)25(18,22)23)24-16(21)19(15(13)20)12-8-4-5-9-17-12/h2-9H,1H3
IUPAC Name
8-methyl-5-(pyridin-2-yl)-3-oxa-9λ⁶-thia-5,8-diazatricyclo[8.4.0.0²,⁷]tetradeca-1(14),2(7),10,12-tetraene-4,6,9,9-tetrone
SMILES
CN1C2=C(OC(=O)N(C2=O)C2=CC=CC=N2)C2=CC=CC=C2S1(=O)=O

Pharmacology

Indication

Droxicam is an NSAID previously used for the treatment of inflammation and rheumatoid arthritis [4].

Pharmacodynamics

Droxicam is a prodrug of Piroxicam [1]. Droxicam administration produces anti-inflammatory, antirheumatic, analgesic, and antipyretic effects similar to Piroxicam.

Mechanism of action

Droxicam is converted to Piroxicam via hydrolysis of the ester group in the intestine [2]. Droxicam administration inhibits the synthesis of prostaglandins by cyclooxygenase enzymes [1].

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Tmax of 7 h. Bioavailability equivalent to Piroxicam which is thought to be completely absorbed in humans based on data from rabbits [2].

Volume of distribution

Data not available for prodrug. See Piroxicam for information on the active compound.

Protein binding

Data not available for prodrug. See Piroxicam for information on the active compound.

Metabolism

Converted to Piroxicam via ester hydrolysis [2].

Route of elimination

Data not available for prodrug. See Piroxicam for information on the active compound.

Half life

Data not available for prodrug. See Piroxicam for information on the active compound.

Clearance

Data not available for prodrug. See Piroxicam for information on the active compound.

Toxicity

Exposure to Droxicam is associated with significantly increased risk of hepatic toxicity resulting in its withdrawal from the market [3].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Droxicam.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Droxicam is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Droxicam is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Droxicam is combined with 5-androstenedione.Experimental, Illicit
AbciximabDroxicam may increase the anticoagulant activities of Abciximab.Approved
AcebutololDroxicam may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Droxicam.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Droxicam is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolDroxicam may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Droxicam.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Droxicam.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Droxicam.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Droxicam is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Droxicam is combined with Alendronic acid.Approved
AliskirenDroxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Droxicam.Experimental
AlprenololDroxicam may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Droxicam.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Droxicam is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Droxicam is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideDroxicam may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Droxicam is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Droxicam.Approved
AncrodDroxicam may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Droxicam.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Droxicam is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Droxicam is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Droxicam is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Droxicam.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Droxicam.Approved, Investigational
Antithrombin III humanDroxicam may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Droxicam is combined with Antrafenine.Approved
ApixabanDroxicam may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Droxicam.Investigational
ApramycinDroxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Droxicam.Approved, Investigational
ArbekacinDroxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinDroxicam may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanDroxicam may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololDroxicam may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineDroxicam may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Droxicam is combined with Atamestane.Investigational
AtenololDroxicam may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Droxicam.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Droxicam.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Droxicam is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Droxicam.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Droxicam.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Droxicam is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Droxicam.Approved, Investigational
BazedoxifeneDroxicam may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminDroxicam may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Droxicam.Approved, Investigational
BefunololDroxicam may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinDroxicam may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Droxicam.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Droxicam.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Droxicam.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Droxicam.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Droxicam.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Droxicam.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Droxicam.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Droxicam.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Betamethasone.Approved, Vet Approved
BetaxololDroxicam may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Droxicam.Approved, Investigational
BevantololDroxicam may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Droxicam.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Droxicam.Approved, Investigational
BisoprololDroxicam may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinDroxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololDroxicam may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Droxicam.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Droxicam.Investigational
BucindololDroxicam may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Droxicam.Approved
BufexamacThe risk or severity of adverse effects can be increased when Droxicam is combined with Bufexamac.Approved, Experimental
BufuralolDroxicam may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Droxicam.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Droxicam.Approved
BupranololDroxicam may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Droxicam.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Droxicam.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Droxicam is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Droxicam is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Droxicam.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Droxicam.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Droxicam.Approved, Vet Approved, Withdrawn
CarteololDroxicam may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolDroxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Droxicam.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Droxicam.Approved, Investigational
CeliprololDroxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinDroxicam may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Droxicam.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Droxicam.Approved, Vet Approved
ChlorotrianiseneDroxicam may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Droxicam is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Droxicam.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Droxicam.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Droxicam is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Droxicam is combined with Cimicoxib.Investigational
CinoxacinDroxicam may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinDroxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Droxicam is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Droxicam.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Droxicam is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Droxicam is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Droxicam is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Droxicam is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Droxicam.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Droxicam.Vet Approved
CloranololDroxicam may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneDroxicam may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensDroxicam may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Droxicam is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Droxicam is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Droxicam is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Droxicam.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Droxicam.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Droxicam is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateDroxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinDroxicam may increase the thrombogenic activities of Daidzein.Experimental
DalteparinDroxicam may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDroxicam may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Droxicam.Investigational
DarexabanDroxicam may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Droxicam is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Droxicam is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Delapril.Investigational
DesipramineDroxicam may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinDroxicam may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Droxicam is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Droxicam is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Droxicam is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Droxicam is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Droxicam.Approved, Investigational
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Droxicam.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Droxicam is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Droxicam is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Droxicam.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Droxicam.Experimental
DextranDroxicam may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinDroxicam may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Droxicam is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Droxicam.Approved, Vet Approved
DicoumarolDroxicam may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolDroxicam may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolDroxicam may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Droxicam.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Droxicam.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Droxicam is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Droxicam is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Droxicam.Approved
DihydrostreptomycinDroxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Droxicam.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Droxicam.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Droxicam.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Droxicam.Approved
DiphenadioneDroxicam may increase the anticoagulant activities of Diphenadione.Experimental
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Droxicam.Approved
DrospirenoneDroxicam may increase the hyperkalemic activities of Drospirenone.Approved
DuloxetineDuloxetine may increase the antiplatelet activities of Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Droxicam.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Droxicam.Investigational
Edetic AcidDroxicam may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDroxicam may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Droxicam.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Droxicam is combined with Enalaprilat.Approved
EnoxacinDroxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinDroxicam may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Droxicam.Experimental
EpanololDroxicam may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolDroxicam may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Droxicam.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Droxicam.Experimental
EplerenoneDroxicam may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Droxicam.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Droxicam.Approved
EquileninThe risk or severity of adverse effects can be increased when Droxicam is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Droxicam is combined with Equilin.Approved
EquolDroxicam may increase the thrombogenic activities of Equol.Investigational
EsatenololDroxicam may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Droxicam.Approved, Investigational
EsmololDroxicam may decrease the antihypertensive activities of Esmolol.Approved
Estradiol acetateDroxicam may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateDroxicam may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateDroxicam may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolDroxicam may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedDroxicam may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Droxicam is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Droxicam is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Droxicam.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Droxicam.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Droxicam.Experimental
Ethyl biscoumacetateDroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Droxicam is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Droxicam.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Droxicam.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Droxicam.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Droxicam.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Droxicam.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Droxicam.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Droxicam.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Droxicam.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Droxicam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Droxicam.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Droxicam.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Droxicam.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Droxicam.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Droxicam.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Droxicam.Approved, Investigational
FleroxacinDroxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Droxicam.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Fludrocortisone.Approved, Investigational
FluindioneDroxicam may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineDroxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Droxicam is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Droxicam.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Droxicam.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Droxicam.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Droxicam.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Droxicam is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Droxicam.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Droxicam.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Droxicam.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Droxicam.Approved, Nutraceutical, Vet Approved
FondaparinuxDroxicam may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Droxicam.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Droxicam is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Fosinopril.Approved
FramycetinDroxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Droxicam.Approved, Vet Approved
GabexateDroxicam may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinDroxicam may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinDroxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Droxicam.Approved, Withdrawn
GemifloxacinDroxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinDroxicam may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinDroxicam may increase the thrombogenic activities of Genistein.Investigational
GentamicinDroxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ADroxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Droxicam is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Droxicam.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Droxicam.Approved
GrepafloxacinDroxicam may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Droxicam.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Droxicam.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Droxicam is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Droxicam is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Droxicam is combined with HE3286.Investigational
HeparinDroxicam may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolDroxicam may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Droxicam.Investigational
HydralazineDroxicam may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Droxicam.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Droxicam.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Droxicam.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Droxicam.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Droxicam.Approved, Investigational
Hygromycin BDroxicam may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Droxicam.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Droxicam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Droxicam.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Droxicam is combined with Icosapent.Approved, Nutraceutical
IdraparinuxDroxicam may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Droxicam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Droxicam.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Droxicam.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Droxicam.Approved
IndenololDroxicam may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Droxicam.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Droxicam.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Droxicam.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Droxicam.Approved, Investigational
IsepamicinDroxicam may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Droxicam.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Droxicam.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Droxicam is combined with Istaroxime.Investigational
KanamycinDroxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Droxicam.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Droxicam.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Droxicam.Approved
LabetalolDroxicam may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Droxicam.Approved, Investigational
LandiololDroxicam may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Droxicam.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Droxicam.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Droxicam.Approved, Investigational
LepirudinDroxicam may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Droxicam.Approved, Investigational
LetaxabanDroxicam may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololDroxicam may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololDroxicam may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinDroxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Droxicam.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Droxicam.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Droxicam.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Droxicam.Experimental
LomefloxacinDroxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Droxicam.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Droxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Droxicam.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Droxicam is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Droxicam.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Droxicam.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Droxicam.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Droxicam.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Droxicam.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Droxicam.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Droxicam.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Droxicam is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Droxicam.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Droxicam.Approved
MelagatranDroxicam may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Droxicam is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Droxicam.Approved, Vet Approved
MepindololDroxicam may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Droxicam.Approved
MestranolDroxicam may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Droxicam.Approved, Investigational, Withdrawn
MethallenestrilDroxicam may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Droxicam.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Droxicam.Approved
Methyl salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Droxicam.Approved, Vet Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Droxicam.Approved, Vet Approved
MetipranololDroxicam may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Droxicam.Approved
MetoprololDroxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Droxicam.Investigational, Withdrawn
MicronomicinDroxicam may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Droxicam.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Droxicam.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Droxicam.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Droxicam.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Droxicam.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Droxicam.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Droxicam.Approved
MoxestrolDroxicam may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinDroxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Droxicam.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Droxicam.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Droxicam.Approved
NadololDroxicam may decrease the antihypertensive activities of Nadolol.Approved
NadroparinDroxicam may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Droxicam.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Droxicam.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Droxicam.Investigational
Nalidixic AcidDroxicam may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Droxicam.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Droxicam is combined with NCX 1022.Investigational
NeamineDroxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololDroxicam may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Droxicam.Approved, Withdrawn
NemonoxacinDroxicam may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Droxicam is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Droxicam.Approved, Investigational
NetilmicinDroxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Droxicam.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Droxicam.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Droxicam.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Droxicam.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Droxicam.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Droxicam.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Droxicam.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Droxicam.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Droxicam.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Droxicam.Investigational
NorfloxacinDroxicam may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinDroxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Droxicam is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Droxicam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Droxicam.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Droxicam.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Droxicam is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Droxicam is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Droxicam.Vet Approved
OtamixabanDroxicam may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Droxicam.Approved
Oxolinic acidDroxicam may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololDroxicam may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Droxicam.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Droxicam.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Droxicam is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Droxicam.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Droxicam is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Droxicam.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Droxicam.Approved, Investigational
PazufloxacinDroxicam may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinDroxicam may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololDroxicam may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateDroxicam may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateDroxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Perindopril.Approved
PhenindioneDroxicam may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonDroxicam may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Droxicam.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Droxicam.Approved, Investigational
PindololDroxicam may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidDroxicam may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Droxicam.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Droxicam.Approved, Investigational
Piromidic acidDroxicam may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Droxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Droxicam.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Droxicam is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorDroxicam may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinDroxicam may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateDroxicam may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Droxicam.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Droxicam is combined with Pomalidomide.Approved
Potassium CitrateDroxicam may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololDroxicam may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Droxicam.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Droxicam.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Droxicam is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Droxicam is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Droxicam is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Droxicam.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Droxicam is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Droxicam is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Droxicam can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Droxicam.Experimental
PromestrieneDroxicam may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Droxicam.Approved, Investigational
PropafenoneDroxicam may decrease the antihypertensive activities of Propafenone.Approved
PropranololDroxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Droxicam.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Droxicam.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Droxicam.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Droxicam.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Droxicam.Vet Approved
Protein CDroxicam may increase the anticoagulant activities of Protein C.Approved
Protein S humanDroxicam may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDroxicam may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinDroxicam may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Droxicam.Investigational
PuromycinDroxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Quinapril.Approved, Investigational
QuinestrolDroxicam may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Droxicam.Approved
RamiprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Droxicam is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Droxicam.Approved, Experimental, Investigational
ReviparinDroxicam may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinDroxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Droxicam is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Droxicam is combined with Risedronate.Approved, Investigational
RivaroxabanDroxicam may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Droxicam.Approved, Investigational, Withdrawn
RosoxacinDroxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinDroxicam may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Droxicam.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Droxicam.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Droxicam.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Droxicam.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Droxicam.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Droxicam.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Droxicam.Approved, Investigational
SecoisolariciresinolDroxicam may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Droxicam is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Droxicam.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Droxicam.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Droxicam.Investigational
SertralineSertraline may increase the antiplatelet activities of Droxicam.Approved
SisomicinDroxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinDroxicam may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Droxicam.Approved
SotalolDroxicam may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinDroxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Droxicam.Investigational
StreptomycinDroxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Droxicam.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Droxicam.Approved, Investigational
SulodexideDroxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Droxicam.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Droxicam.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Droxicam.Experimental
Synthetic Conjugated Estrogens, ADroxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BDroxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusDroxicam may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Droxicam.Approved
TalinololDroxicam may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Droxicam.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Droxicam.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Droxicam.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Droxicam is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Droxicam is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Droxicam.Approved, Investigational
TemafloxacinDroxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Droxicam.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Droxicam is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Droxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Droxicam.Vet Approved
TerbutalineDroxicam may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Droxicam.Approved
TertatololDroxicam may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Droxicam.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Droxicam.Approved
TiboloneDroxicam may increase the thrombogenic activities of Tibolone.Approved, Investigational
Tiludronic acidThe risk or severity of adverse effects can be increased when Droxicam is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololDroxicam may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Droxicam.Investigational
TioclomarolDroxicam may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Droxicam is combined with Tixocortol.Approved, Withdrawn
TobramycinDroxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Droxicam is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Droxicam.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Droxicam.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Droxicam.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Droxicam.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Droxicam is combined with Triamcinolone.Approved, Vet Approved
TriamtereneDroxicam may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Droxicam.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Droxicam.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Droxicam.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Droxicam is combined with Trolamine salicylate.Approved
TrovafloxacinDroxicam may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinDroxicam may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Droxicam is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Droxicam.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Droxicam.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Droxicam.Approved, Investigational
VancomycinDroxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Droxicam.Approved
WarfarinDroxicam may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDroxicam may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Droxicam.Approved, Investigational
ZeranolDroxicam may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Droxicam.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Droxicam.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Droxicam is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Droxicam.Withdrawn
Food Interactions
Not Available

References

General References
  1. Esteve J, Farre AJ, Roser R: Pharmacological profile of droxicam. Gen Pharmacol. 1988;19(1):49-54. [PubMed:3278945]
  2. Olkkola KT, Brunetto AV, Mattila MJ: Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107-20. [PubMed:8162655]
  3. Lapeyre-Mestre M, de Castro AM, Bareille MP, Del Pozo JG, Requejo AA, Arias LM, Montastruc JL, Carvajal A: Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol. 2006 Aug;20(4):391-5. doi: 10.1111/j.1472-8206.2006.00416.x. [PubMed:16867024]
  4. WHO: Droxicam [Link]
External Links
KEGG Drug
D07267
PubChem Compound
65679
PubChem Substance
310265122
ChemSpider
59108
ChEBI
76133
ChEMBL
CHEMBL1213420
PharmGKB
PA166049182
Wikipedia
Droxicam
ATC Codes
M01AC04 — Droxicam
MSDS
Download (263 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0319 mg/mLALOGPS
logP1.75ALOGPS
logP1.23ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)0.92ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area96.88 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity88.19 m3·mol-1ChemAxon
Polarizability33.9 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Not Available
Direct Parent
Benzothiazines
Alternative Parents
Pyridines and derivatives / Organosulfonamides / Benzenoids / Heteroaromatic compounds / Lactams / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds
show 2 more
Substituents
Benzothiazine / Pyridine / Benzenoid / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Heteroaromatic compound / Lactam / Oxacycle / Azacycle
show 8 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heterotricyclic compound, pyridines, ring assembly (CHEBI:76133)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
Curator comments
Droxicam is converted to Piroxicam which acts on the target.
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Esteve J, Farre AJ, Roser R: Pharmacological profile of droxicam. Gen Pharmacol. 1988;19(1):49-54. [PubMed:3278945]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
Curator comments
Droxicam is converted to Piroxicam which acts on the target.
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Esteve J, Farre AJ, Roser R: Pharmacological profile of droxicam. Gen Pharmacol. 1988;19(1):49-54. [PubMed:3278945]

Drug created on October 21, 2015 10:02 / Updated on August 02, 2018 06:15